Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleoredoxin-like protein 1 (Nxnl1, also known as rod-derived cone viability factor or RdCVF) is a secreted trophic factor with oxidoreductase activity that is primarily expressed in the retina. It is essential for the long-term survival and function of cone photoreceptors by protecting them from oxidative stress and by promoting glucose uptake via a receptor complex involving GLUT1 and BSG proteins[1][5][7][8]. Loss of Nxnl1 expression leads to cone degeneration and is implicated in retinal diseases such as retinitis pigmentosa. While it belongs to the thioredoxin superfamily, Nxnl1 has both enzymatic and signaling roles, with unique properties distinct from canonical nucleoredoxins. There is ongoing research into its therapeutic potential for neurodegenerative diseases of the eye.
Promotes survival of cone photoreceptors by protecting them from oxidative stress; Facilitates glucose uptake in cones through interaction with glucose transporter complex
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleoredoxin-like protein 1 (Nxnl1).